Disclosed is the use of temozolomide or a pharmaceutically acceptable salt thereof for the manufacture of a formulation for the treatment of a proliferative disorder in a patient, wherein the treatment comprises administering a dose of 150 mg/m2 of temozolomide to the patient by intravenous infusion over a period of about 90 minutes, wherein the administration achieves an arithmetic maximum plasma concentration (Cmax) of temozolomide in the range of about 5.5 to about 10.6 ìg/mL and an arithmetic maximum plasma concentration (Cmax) of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC) in the range of about 137 to about 916 ng/mL.
